EZH2 and leukemia: More than 80% of patients with overt-PMF carry variants/mutations other than JAK2/CALR/MPL, in particular high-risk mutations which are associated with overall prognosis and leukemia-free survival (ASXL1, SRSF2, IDH1/IDH2, EZH2) [35].